Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Simon Diallo

Showing results (71-80 of 92) with videos related to

Pageof 10
Sort By:
Molecular Therapy. Methods & Clinical Development|October 12, 2023
A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infectionStephen Boulton, Joanna Poutou, Rida Gill, et al.
Scientific Reports|May 27, 2016
First-in-class small molecule potentiators of cancer virotherapyMark H Dornan, Ramya Krishnan, Andrew M Macklin, et al.
Cell Reports|July 6, 2024
A cyclic lipopeptide from Fusarium graminearum targets plant membranes to promote virulenceElizabeth K Brauer, Whynn Bosnich, Kirsten Holy, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 22, 2011
The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancersKelley A Parato, Caroline J Breitbach, Fabrice Le Boeuf, et al.
Membranes|September 3, 2020
Implications for SARS-CoV-2 Vaccine Design: Fusion of Spike Glycoprotein Transmembrane Domain to Receptor-Binding Domain Induces TrimerizationTaha Azad, Ragunath Singaravelu, Mathieu J F Crupi, et al.
International Journal of Molecular Sciences|March 6, 2021
Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD InteractionEmily E F Brown, Reza Rezaei, Taylor R Jamieson, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 5, 2012
Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccineChantal G Lemay, Julia L Rintoul, Agnieszka Kus, et al.
Plos Pathogens|August 24, 2018
Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axisChadi Zakaria, Polen Sean, Huy-Dung Hoang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 12, 2021
Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entryTaha Azad, Ragunath Singaravelu, Zaid Taha, et al.
Nature|September 3, 2011
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humansCaroline J Breitbach, James Burke, Derek Jonker, et al.
Pageof 10

Showing results (71-80 of 92) with videos related to

Sort By:
Pageof 10
Molecular Therapy. Methods & Clinical Development|October 12, 2023
A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infectionStephen Boulton, Joanna Poutou, Rida Gill, et al.
Scientific Reports|May 27, 2016
First-in-class small molecule potentiators of cancer virotherapyMark H Dornan, Ramya Krishnan, Andrew M Macklin, et al.
Cell Reports|July 6, 2024
A cyclic lipopeptide from Fusarium graminearum targets plant membranes to promote virulenceElizabeth K Brauer, Whynn Bosnich, Kirsten Holy, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 22, 2011
The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancersKelley A Parato, Caroline J Breitbach, Fabrice Le Boeuf, et al.
Membranes|September 3, 2020
Implications for SARS-CoV-2 Vaccine Design: Fusion of Spike Glycoprotein Transmembrane Domain to Receptor-Binding Domain Induces TrimerizationTaha Azad, Ragunath Singaravelu, Mathieu J F Crupi, et al.
International Journal of Molecular Sciences|March 6, 2021
Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD InteractionEmily E F Brown, Reza Rezaei, Taylor R Jamieson, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 5, 2012
Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccineChantal G Lemay, Julia L Rintoul, Agnieszka Kus, et al.
Plos Pathogens|August 24, 2018
Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axisChadi Zakaria, Polen Sean, Huy-Dung Hoang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 12, 2021
Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entryTaha Azad, Ragunath Singaravelu, Zaid Taha, et al.
Nature|September 3, 2011
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humansCaroline J Breitbach, James Burke, Derek Jonker, et al.
Pageof 10